Rising Pharma Holdings recalled 13,440 bottles of Cetirizine Hydrochloride Tablets on September 12, 2025. The tablets are imprinted with incorrect identification. This recall affects consumers nationwide.
Tablet/Capsules Imprinted with Wrong ID
Consumers and healthcare providers should stop using this product immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Cetirizine Hydrochloride Tablets USP 10 mg, packaged in 500-tablet bottles. Manufactured by Unique Pharmaceuticals Labs in Mumbai, India, it is distributed by Rising Pharma Holdings, Inc. The affected lot numbers are PY925014 and PY925013, with an expiration date of January 31, 2028.
The tablets are imprinted with the wrong identification, which poses a risk of incorrect medication being dispensed. This error can lead to serious health consequences for users.
No injuries or incidents have been reported due to the mislabeling as of the recall date. However, the potential for harm remains high.
Consumers should stop using the product immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for guidance and possible return instructions.
For more information, consumers can visit the FDA website or contact Rising Pharma Holdings directly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.